A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy

Overview

A study to describe real-world treatment patterns and overall survival in advanced liver cancer participants who received second or third line nivolumab therapy

Full Title of Study: “Overall Survival and Treatment Patterns for Advanced Hepatocellular Carcinoma Patients Who Received Second or Third Line Nivolumab Therapy”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: November 15, 2018

Detailed Description

The central aims of this study are descriptive and designed to describe the patient demographics, clinical characteristics, treatment patterns, and overall survival in advanced liver cancer participants who received second or third line nivolumab therapy in the real-world setting.

Arms, Groups and Cohorts

  • Advanced Hepatocellular Carcinoma (aHCC) cohort
    • aHCC cohort selected from the Flatiron Health Oncology electronic health record (EHR) data from January 2011 to the most recent data available. The index date will be defined as the start of second or third line nivolumab therapy for aHCC between January 1, 2011 and the most recent data available.

Clinical Trial Outcome Measures

Primary Measures

  • Treatment patterns
    • Time Frame: From aHCC diagnosis date to first nivolumab treatment (Up to 7.75 years)
    • Nivolumab second and third lines of therapy will be described including prior lines of therapy, duration of nivolumab therapy and time from aHCC diagnosis date to first nivolumab treatment
  • Overall Survival
    • Time Frame: From start date of 2L and 3L nivolumab therapy to the date of death (Up to 7.75 years)
    • The initial second or third line nivolumab therapy date will be used as the start date for the OS analysis. Occurrence of death will be considered as event and the duration for event will be calculated as time from 2L or 3L nivolumab therapy date to death date. Patients who survived will be censored and their duration period will be the time between the initial 2L or 3L nivolumab therapy date and the last date of their post-period follow up

Participating in This Clinical Trial

Inclusion Criteria

  • Adult aHCC participants in the Flatiron database as defined by: – Diagnosed with HCC International Classification of Diseases (ICD)-9 155.x or ICD-10 C22.x) – Pathology consistent with advanced HCC – Age 18 years or older at index – At least two clinic encounters on different days in the Flatiron database occurring on or after January 1, 2011 – Participants who received second or third line nivolumab monotherapy or combination therapy for aHCC Exclusion Criteria:

  • Participants with <1 month of medical data (any clinic visits, medication administrations or oral medication prescriptions) following and including the index date – Participants with clinical study drug during prior or post study index periods Other protocol-defined inclusion/exclusion criteria could apply

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Bristol-Myers Squibb
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.